Xcout Intel
Alterome Therapeutics, Inc.
Alterome Therapeutics, Inc. is a clinical-stage precision oncology company headquartered in San Diego, California, founded in 2021. The privately held biotech firm focuses on developing targeted therapies to address genomically defined cancer drivers and intractable oncological targets.
Subscribe to see Alterome Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Alterome Therapeutics, Inc. at a glance
Alterome Therapeutics, Inc. is a biotech company headquartered in United States. Its most recent funding round, Series B, raised $132M in April 2024. Xcout tracks 25 named people at Alterome Therapeutics, Inc., including Jung Choi (CEO). Xcout recorded 2 job postings from Alterome Therapeutics, Inc. in the last 90 days.
Alterome Therapeutics, Inc. leadership
- Jung ChoiCEO
- Scott MoorefieldCOO & CBO
- Johanna MyletCFO
- Leonardo FaoroCMO
- Ryan Corcoran, MD, PhDCo-founder, SAB Chair
- John HuangSVP, Biology
19 more named people on record for Alterome Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Alterome Therapeutics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $132M | — | |
| Series A | $100M | — | |
| SEC Form D filing | $63.8M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Alterome Therapeutics, Inc.
Xcout recorded 2 job postings from Alterome Therapeutics, Inc. in the last 90 days, from a hiring record Xcout has kept since July 2026.
The weekly hiring trend, the roles and locations behind it — see Alterome Therapeutics, Inc.'s hiring signals →
Tech stack
Alterome Therapeutics, Inc. competitors
A few of Alterome Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Apeiron Therapeutics is a clinical-stage biopharmaceutical and precision oncology company focused on developing biomarker-driven therapeutics for cancer.
Turning Point Therapeutics is a clinical-stage precision oncology company based in San Diego, California, that designs and develops targeted cancer therapies. Founded in 2013, the company operates as a subsidiary of Bristol Myers Squibb following its acquisition in 2022.
AUM Biosciences is a clinical-stage biotechnology company that develops precision oncology therapeutics utilizing multi-faceted inhibition strategies to overcome cancer drug resistance. The company serves patients and the healthcare sector by advancing a targeted clinical pipeline designed to combat tumor evasion and treatment resistance.
Mirador Therapeutics, Inc. is a clinical-stage precision medicine company headquartered in San Diego, California, focused on developing first- and best-in-class next-generation therapeutics.
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
OncXerna Therapeutics is a clinical-stage precision-oncology biotechnology company that develops RNA-based biomarkers and targeted cancer therapies. Its work is intended to help identify cancer patients most likely to benefit from particular treatments and support oncologists and pharmaceutical partners in treatment selection.
Get Alterome Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Alterome Therapeutics, Inc. in Xcout Intel
- 25 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- The full competitor set, tracking, exports and API access